What is the primary purpose of the Generics Act of 1988 (RA 6675)?

The primary purpose of RA 6675 is to promote, require, and ensure the production, marketing, and distribution of essential drugs and medicines identified by their generic names, thereby making quality essential drugs more accessible and affordable to the public.

Who are the key individuals and entities covered by the provisions of RA 6675?

The Act covers prescribers (physicians, dentists, veterinarians), pharmacists, drug manufacturers, importers, distributors, wholesalers, retailers, and even the patients themselves through their right to choose.

What is the distinction between a 'generic name' and a 'brand name' according to RA 6675?

A 'generic name' refers to the internationally accepted non-proprietary name of a drug, as determined by the Bureau of Food and Drugs (now FDA). A 'brand name' is the proprietary name given by the manufacturer to distinguish its product from others.

What is the mandatory role of a prescriber under RA 6675 regarding prescriptions?

Prescribers are mandated to write prescriptions using the generic name of the drug. They may include the brand name in parentheses after the generic name, but the generic name must always be present and legible.

What are the core responsibilities of a pharmacist when dispensing drugs under the Generics Act?

Pharmacists must inform patients of all available generic equivalents, their corresponding prices, and any differences in appearance. They must also dispense drugs using their generic names, ensuring patient understanding and choice.

What are the potential penalties for violating the Generics Act?

Violations can lead to administrative fines, suspension or revocation of professional license (for prescribers and pharmacists), closure of establishments, and even imprisonment, depending on the nature and repetition of the offense.

Does the Generics Act prohibit the sale of brand-name drugs?

No, the Act does not prohibit the sale of brand-name drugs. Instead, it mandates that generic names be used in all aspects of drug distribution and that patients be informed of generic alternatives to ensure they have the option to choose more affordable medicines.

Mastering the Generics Act of 1988 (RA 6675) for the PhLE (Licensure Exam) Pharm. Jurisprudence and Ethics Exam

Introduction: The Generics Act of 1988 (RA 6675) and Your PhLE Success

As an aspiring pharmacist in the Philippines, understanding the legal framework governing pharmaceutical practice is not just a matter of compliance—it's a cornerstone of your professional competence and a critical component of the Complete PhLE (Licensure Exam) Pharm. Jurisprudence and Ethics Guide. Among the foundational laws, Republic Act No. 6675, more commonly known as the Generics Act of 1988, stands out. Enacted to promote and ensure the availability of cheaper, quality essential drugs to the Filipino people, this Act profoundly impacts the daily practice of pharmacy.

For the PhLE (Licensure Exam) Pharm. Jurisprudence and Ethics exam, RA 6675 is a high-yield topic. Questions pertaining to this law frequently appear, testing your knowledge of its core provisions, the responsibilities it imposes on healthcare professionals (especially pharmacists), and its practical implications in various scenarios. A solid grasp of the Generics Act will not only boost your exam score but also prepare you for ethical and legal dispensing practices in your future career.

Key Concepts of the Generics Act of 1988 (RA 6675)

To truly master RA 6675 for the PhLE, it's essential to delve into its fundamental principles and specific provisions. This Act revolutionized drug prescribing, dispensing, and labeling in the Philippines.

Declaration of Policy (Section 2)

The Act declares it a policy of the State to promote, require, and ensure the production, marketing, and distribution of essential drugs identified by their generic names. The ultimate goal is to make quality essential drugs more accessible and affordable to the public, thereby promoting health and saving lives.

Definition of Terms (Section 3)

Understanding these definitions is crucial:

Generic Name: This refers to the internationally accepted non-proprietary name of a drug, as determined by the Bureau of Food and Drugs (now part of the Food and Drug Administration, FDA). Examples include "Paracetamol," "Amoxicillin," and "Metformin."
Brand Name: This is the proprietary name given by a manufacturer to distinguish its product from those of competitors. For instance, "Biogesic" for Paracetamol or "Amoxil" for Amoxicillin.
Drug Product: Refers to the finished pharmaceutical preparation containing an active ingredient, whether alone or in combination with others, intended for human or animal use.

Mandatory Use of Generic Names (Section 4)

This is perhaps the most impactful provision. It mandates the use of generic terminology in all aspects of drug handling:

Prescription Writing: All government and private medical, dental, and veterinary practitioners are required to use the generic name of the drug in their prescriptions. They may include the brand name in parentheses after the generic name, but the generic name must always be present, legible, and clearly written.
Dispensing: Pharmacists, whether in government or private pharmacies, are mandated to inform the patient of all available generic equivalents, their corresponding prices, and any differences in appearance. The patient then has the right to choose the specific drug product (generic or brand) they prefer. Pharmacists must dispense the drug by its generic name.
Labeling: All drug manufacturers, importers, and distributors are required to print the generic name of the drug product prominently and in bigger letters than the brand name on the label, packaging, and advertising materials.

Responsibilities of Healthcare Professionals and Establishments

For Prescribers (Physicians, Dentists, Veterinarians):

Write prescriptions using generic names.
Ensure legibility and completeness of prescriptions.
Inform patients about the generic names of the prescribed drugs.
Avoid writing "no substitution" or "do not substitute" on prescriptions, as this is illegal under the Act.

For Pharmacists:

Pharmacists play a pivotal role in implementing the Generics Act. Their responsibilities include:

Patient Counseling: Actively informing the patient or their representative of all available generic equivalents for the prescribed drug, including their prices and differences in appearance (e.g., shape, color).
Offering Choices: Providing the patient with the option to choose between generic and brand-name drugs, ensuring informed consent.
Dispensing by Generic Name: Regardless of whether a brand name was also written on the prescription, the pharmacist must dispense the drug and indicate it on the label using its generic name.
Maintaining Records: Keeping proper records of dispensed drugs.
Refusal to Dispense: A pharmacist may refuse to dispense a drug product if the prescription is incomplete, illegible, or contains "no substitution" instructions, provided the prescriber is immediately informed for clarification or correction.

For Drug Manufacturers, Importers, Distributors, and Retailers:

Prominently display the generic name on labels, packaging, and advertising materials, ensuring it is larger than the brand name.
Ensure the availability of essential drugs by their generic names.
Display a list of drug products by generic names, with their corresponding brand names and prices, in their establishments.

Prohibited Acts and Penalties (Section 6)

Violations of the Generics Act carry significant penalties, ranging from fines to imprisonment and professional license revocation:

First Offense: Fine of not less than Ten Thousand Pesos (P10,000) but not more than Forty Thousand Pesos (P40,000).
Second Offense: Fine of not less than Forty Thousand Pesos (P40,000) but not more than One Hundred Fifty Thousand Pesos (P150,000) and suspension of license to operate for one year.
Third Offense: Fine of not less than One Hundred Fifty Thousand Pesos (P150,000) but not more than Five Hundred Thousand Pesos (P500,000) and permanent revocation of license to operate.
For healthcare professionals, repeated violations can lead to the suspension or revocation of their professional license by the Professional Regulation Commission (PRC).
Any government official or employee who violates the Act shall also be subject to administrative and criminal penalties.

How It Appears on the Exam

The PhLE (Licensure Exam) Pharm. Jurisprudence and Ethics exam tests your understanding of RA 6675 through various question formats. Expect a mix of:

Direct Recall Questions: These will test your knowledge of specific definitions (e.g., generic vs. brand name), the declared policy, or the exact penalties for a given offense.
Scenario-Based Questions: These are common and require you to apply the law to a practical situation. For instance:
"A patient presents a prescription for 'Amoxil 500mg' with no generic name indicated. What is the pharmacist's primary action according to RA 6675?" (Answer: Inform the patient of available generic Amoxicillin, its price, and differences, and dispense Amoxicillin.)

"A physician writes a prescription with 'Paracetamol 500mg' but adds 'NO SUBSTITUTION' next to it. What should the pharmacist do?" (Answer: Advise the physician that the 'NO SUBSTITUTION' instruction is illegal and clarify the prescription, refusing to dispense until corrected.)
Ethical Dilemma Questions: While primarily a legal act, RA 6675 has strong ethical underpinnings concerning patient welfare and access. Questions might explore the ethical responsibility of a pharmacist in promoting generics.
Identification of Prohibited Acts: You might be asked to identify which actions constitute a violation of the Generics Act.

Familiarizing yourself with the nuances of these question types through PhLE (Licensure Exam) Pharm. Jurisprudence and Ethics practice questions is highly recommended.

Study Tips for Mastering the Generics Act

Approaching RA 6675 strategically can make a significant difference in your exam preparation:

Read the Full Act: While this article provides a comprehensive overview, reading the actual text of RA 6675 will give you the precise legal language and context. Pay close attention to sections 2, 3, 4, and 6.
Focus on Pharmacist Responsibilities: As a future pharmacist, your duties under this Act are paramount. Create a checklist or flowchart of what a pharmacist must do and must not do when receiving a prescription and dispensing drugs.
Understand the "Why": Don't just memorize; understand the rationale behind the law (accessibility, affordability, patient rights). This understanding helps you answer scenario-based questions more effectively.
Create Flashcards for Definitions and Penalties: Key terms like "generic name," "brand name," and the specific penalties for first, second, and third offenses are prime candidates for memorization via flashcards.
Practice Scenario Analysis: Work through various hypothetical situations. What if a prescription only has a brand name? What if a patient insists on a brand name despite generic availability? What if the generic is out of stock?
Utilize Practice Questions: Engage with as many free practice questions as possible that specifically cover RA 6675. This helps identify weak areas and familiarizes you with exam question styles.
Connect to Other Laws: Briefly consider how RA 6675 interacts with other pharmacy laws (e.g., the Pharmacy Law, Dangerous Drugs Act) to develop a holistic understanding of pharmaceutical jurisprudence.

Common Mistakes to Watch Out For

Avoid these common pitfalls when studying and answering questions related to the Generics Act:

Confusing "Generic-Only" with "Generic-First": The Act mandates generic names on prescriptions and labels and informing patients about generics, but it does not prohibit the sale or dispensing of brand-name drugs if the patient chooses them. The choice ultimately rests with the patient after counseling.
Ignoring the "Why": Simply memorizing without understanding the underlying purpose can lead to incorrect application in complex scenarios. Remember, the law aims to empower patients with choices for affordable medicines.
Overlooking Penalties: While less glamorous, the specific fines and potential imprisonment/license revocation are often tested. Know the graduated penalties.
Misunderstanding Pharmacist Counseling Role: A common mistake is thinking the pharmacist merely dispenses what's written. Under RA 6675, the pharmacist has an active role in informing and counseling the patient about generic alternatives.
Not Knowing Prohibited Acts for Prescribers: Forgetting that writing "no substitution" is illegal for prescribers is a frequent error.
Assuming Brand Name Dispensing is Always Illegal: If a patient, after being informed of generic options, still chooses and insists on a brand name drug (and it's available and legally prescribed with its generic name), the pharmacist can dispense it. The key is the patient's informed choice.

Quick Review / Summary

The Generics Act of 1988 (RA 6675) is a cornerstone of Philippine pharmacy law, designed to make essential drugs affordable and accessible. Here’s a concise recap:

Policy: Promote generic drugs for affordability and accessibility.
Key Definitions: Generic name (INN), Brand name (proprietary).
Mandatory Use: Generic names required in prescriptions, dispensing, and labeling.
Prescriber's Duty: Write generic names; brand names optional in parentheses. "No substitution" is illegal.
Pharmacist's Duty: Inform patients of generic alternatives, prices, and differences; dispense by generic name; empower patient choice.
Labeling: Generic name more prominent than brand name.
Penalties: Graduated fines, license suspension/revocation, imprisonment for violations.
Exam Focus: Definitions, responsibilities of pharmacists and prescribers, scenario-based application, and penalties.

By diligently studying these aspects of RA 6675, you'll be well-prepared to tackle relevant questions on your PhLE (Licensure Exam) Pharm. Jurisprudence and Ethics exam and uphold the highest standards of pharmaceutical practice in the Philippines.